Clinical Research Center Sp. z o.o. Medic-R sp.k.

At Clinical Research Center Sp. z o.o. Medic-R sp.k. investigators are evaluating new therapeutic approaches for high‑risk non‑muscle‑invasive bladder cancer and advanced prostate cancer, aiming to improve survival and reduce recurrence.

• Combination of immunotherapy with intravesical BCG
• Targeted agents for PTEN‑deficient metastatic hormone‑sensitive prostate cancer
• Gene‑based therapy to prevent bladder cancer progression

These studies reflect the site’s strong focus on innovative cancer treatments within the urologic oncology field.

The center conducts trials that test acute and preventive therapies for migraine, explore disease‑modifying strategies for progressive multiple sclerosis, and assess novel agents for Tourette syndrome in children and adolescents.

• Acute migraine relief with oral CGRP antagonists
• Neuroprotective treatment to slow brain atrophy in MS
• Oral medication targeting tic severity in Tourette’s

This portfolio highlights a commitment to addressing both common and rare neurological disorders.

Researchers are investigating targeted biologics and immune‑modulating therapies for conditions such as generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and primary Sjögren’s disease, with the goal of improving functional outcomes.

• Antibody‑based treatment to reduce MG‑ADL scores
• Subcutaneous immunoglobulin alternatives for CIDP
• Novel agents to decrease disease activity in Sjögren’s syndrome

The site’s multidisciplinary expertise supports advances in immune‑mediated disorders.

Clinical trials at the Poznan facility evaluate innovative biologics and small molecules for severe skin diseases, including moderate to severe plaque psoriasis, hidradenitis suppurativa, and atopic dermatitis, aiming to achieve rapid skin clearance.

• IL‑23 inhibitor versus placebo in psoriasis
• Anti‑IL‑17 therapy for hidradenitis lesions
• Topical and systemic agents for chronic itch in atopic dermatitis

These programs reflect a strong emphasis on patient‑centered dermatologic care.

The center’s IBD portfolio focuses on improving remission rates for Crohn’s disease and ulcerative colitis through novel induction and maintenance therapies.

• Oral selective kinase inhibitor for ulcerative colitis
• Targeted biologic to achieve endoscopic response in Crohn’s disease
• Combination therapy assessing mucosal healing

Ongoing studies aim to expand treatment options for patients with moderate to severe disease.

Trials investigate preventive and therapeutic strategies for atherosclerotic cardiovascular disease and metabolic conditions such as obesity, including lipid‑lowering antibodies and weight‑loss agents.

• PCSK9 inhibitor to reduce major adverse cardiovascular events
• Novel peptide to promote weight reduction in overweight adults
• Evaluation of anti‑inflammatory therapy on cardiovascular risk

This work supports the site’s commitment to reducing cardiovascular morbidity.

Research at the center includes studies on severe asthma and chronic urticaria, testing inhaled combinations and oral agents to improve lung function and control itching.

• Triple‑therapy inhaler versus standard dual therapy for asthma
• Oral JAK inhibitor for chronic spontaneous urticaria
• Assessment of quality‑of‑life outcomes in allergic disease

These investigations aim to enhance management of chronic respiratory and allergic conditions.